Autoprobiotic enterococci as a component of metabolic syndrome complex therapy

Timely therapy of impaired glucose tolerance (IGT) and metabolically healthy obesity is necessary to prevent serious complications associated with disorders of carbohydrate metabolism (CM) and the development of type 2 diabetes mellitus (DM2).

The aim of the study was to evaluate the effectiveness of autoprobiotics in the treatment of metabolic syndrome (MS) in the initial stage of CM disorders. A study of anthropometric indicators and parameters of CM was conducted in 24 obese patients without CM disorders (group K) and 31 patients with IGT. Patients with MS and obesity were randomized into groups receiving: an autoprobiotic in two courses, for 20 days (AP+), and a placebo (Pl). The AP+ and Pl groups differed from K by a large quantitative content: Bacteroides spp., Prevotella spp., Eubacterium sp., Streptococcus spp. and Roreburia inulinivorans according to PCR-RT. Body weight (BW), body mass index (BMI), concentration of glycated hemoglobin (HbA1c) and serum glucose correlated with these taxa.

In the AP+ group, in contrast to Pl, a gradual decrease in BW, BMI, glucose and HbA1c was revealed, against the background of changes in the composition of the intestinal microbiota: a decrease in the number of streptococci, roseburia, eubacteria prevotella, ruminococci and a tendency to decrease acinetobacter.

The effectiveness of the use of autoprobiotic enterococci in obesity and IGT has been proven. Despite the fact that the mechanisms of their action remain insufficiently studied, their use can be considered as a promising component of the comprehensive prevention and therapy of MS, DM2 and obesity.

1. Chazova IE, Mychka VB, Litvin AYu, et al. Diagnosis and treatment of metabolic syndrome. Russian recommendations (second revision). Cardiovascular therapy and prevention. 2009; 8(6):1–29. In Russian

2. Volovnikova VA, Kotrova AD, Ivanova KA, et al. The role of gut microbiota in the development of obesity. Juvenis scientia. 2019;6:4–10. In Russian

3. Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. The Journal of clinical investigation. 2019;129(10): 4050–4057.

4. Bäckhed F, Manchester J, Semenkovich C, et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proceedings of the National Academy of Sciences. 2007;104: 979–984.

5. Samuel BS, Shaito A, Motoike T, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proceedings of the National Academy of Sciences. 2008;105(43):16767–16772.

6. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61:364–371.

7. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328(5975):228– 231.

8. Duncan SH, Lobley GE, Holtrop G, et al. Human colonic microbiota associated with diet, obesity and weight loss. International journal of obesity. 2008;32(11):1720–1724

9. Tuteja S, Ferguson JF. Gut microbiome and response to cardiovascular drugs. Circulation: Genomic and Precision Medicine. 2019;12(9):421–429.

10. de La Serre CB, Ellis CL, Lee J, et al. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2010;299:G440–G448.

11. Haro C, Garcia-Carpintero S, Alcala-Diaz JF, et al. The gut microbial community in metabolic syndrome patients is modified by diet. The Journal of nutritional biochemistry. 2016;27:27–31

12. Salyers AA, Vercellotti JR, West SE, et al. Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Applied and environmental microbiology. 1977;33(2):319–322

13. Wrzosek L, Miquel S, Noordine ML, et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC biology. 2013;11(1):1–13.

14. Duncan SH, Belenguer A, Holtrop G, et al. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Applied and environmental microbiology. 2007;73(4):1073–1078.

15. Borschev YuI, Ermolenko EI. Metabolic syndrome and intestinal microecology. Translational Medicine. 2014;1:19–28. In Russian [Борщев Ю.Ю., Ермоленко Е.И. Метаболический синдром и микроэкология кишечника. Трансляционная медицина. 2014;1:19–28.]

16. Gareau MG, Sherman PM, Walker WA (2010) Probiotics and the gut microbiota in intestinal health and disease. Nature reviews Gastroenterology & hepatology. 2010;7(9):503–514.

17. Gut microbiome, bacterial metabolism and metabolic disorders. In. Metabolic syndrome. 4th ed. Saint Petersburg: SPSPMU, 2020:67–104. In Russian

18. Lee HY, Park JH, Seok SH, et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show antiobesity effects in diet-induced obese mice. Biochimica et biophysica acta (BBA)-molecular and cell biology of lipids. 2006;1761(7):736–744.

19. Gomes AC, Bueno AA, de Souza RGM, et al. Gut microbiota, probiotics and diabetes. Nutrition journal. 2014;13(1):1–13.

20. Yadav H, Jain S, Sinha P. Effect of Dahi containing Lactococcus lactis on the progression of diabetes induced by a high-fructose diet in rats. Bioscience, biotechnology, and biochemistry. 2006;70(5):1255–8.

21. Anukam KC. Probiotic Toxicity, any evidence? Journal of Pharmacology and Toxicology. 2007;2(7):590– 598.

22. Oleskin AV, Shenderov BA. Probiotics, prebiotics and metabiotics: problems and prospects. Physical and rehabilitation medicine, medical rehabilitation. 2020;2(3):233–243. In Russian

23. Suvorov A, Karaseva A, Kotyleva M, et al. Autoprobiotics as an Approach for Restoration of Personalised Microbiota. Frontiers in microbiology. 2018;12(9):1869.

24. Solovyova OI, Simanenkov VI, Suvorov AN, et al. The use of probiotics and autoprobiotics in the treatment of irritable bowel syndrome. Experimental and clinical gastroenterology. 2017;7(143):115–120. In Russian

25. Suvorov AN, Simanenkov VI, Sundukova ZR, et al. Method for producing autoprobiotic of Enterocuccus faecium being representative of indigenic host intestinal microflora. Patent on the application #2460778С1, 30.12.2010. In Russian

26. Kotrova AD, Shishkin AN, Voropaeva LS, et al. Gender assessment of the gut microbiome in obese patients. Experimental and Clinical Gastroenterology. 2021;10:91–99. In Russian

27. Bakulina NV, Tikhonov SV, Ermolenko EI, et al. Intestinal microbiota, gastroenterological complaints and quality of life in overweight, obese and type 2 diabetes patients. Profilakticheskaya Meditsina. 2022;25(6):80–88. In Russian

28. Santos-Marcos JA, Perez-Jimenez F, Camargo A. The role of diet and intestinal microbiota in the development of metabolic syndrome. The Journal of nutritional biochemistry. 2019;70:1–27.

29. Egshatyan LV, Tkacheva ON, Kafarskaya LI, et al. The changes of gut microbiota associated with age and lifestyle. Obesity and metabolism. 2015;12(2):3–9. In Russian

30. Kvan OV, Konstantinova YuA, Alyokhina GP, et al. The effect of probiotic drugs on hematological blood parameters of laboratory animals. Bulletin of the Orenburg State University. 2017;6(206):76–79. In Russian

31. Li H, Liu F, Lu J, et al. Probiotic mixture of Lactobacillus plantarum strains improves lipid metabolism and gut microbiota structure in high fat diet-fed mice. Frontiers in microbiology. 2020;11:512.

32. Festi D, Schiumerini R, Eusebi LH, et al. Gut microbiota and metabolic syndrome. World journal of gastroenterology: WJG. 2014;20(43):16079–16094.

33. Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ open. 2019;9(3):e017995.

34. Bakulina NV, Tikhonov SV, Ermolenko EI, et al. The use of E. faecium probiotic and autoprobiotic in patients with type 2 diabetes mellitus. HERALD of North-Western State Medical University named after I. I. Mechnikov. 2022;14(1);77–88. In Russian

35. Ermolenko EI, Svirido DA, Kotyleva MP, et al. Correction of rats intestinal dysbiosis using indigenous recombinant strains of enterococci and duration of their persistence in intestinal microbiocenosis. Experimental and clinical gastroenterology. 2016;12:65–69. In Russian

36. Ermolenko E, Simanenkova A, Voropaeva L, et al. Metformin influence on the intestinal microbiota and organism of rats with metabolic syndrome. International Journal of Molecular Sciences. 2022;23(12):6837.

37. Sitkin SI, Tkachenko EI, Vakhitov TYa. The philometabolic core of the intestinal microbiota. Almanac of Clinical Medicine. 2015;40:12–34. In Russian

38. Olivares PDSG, Pacheco ABF, Aranha LN, et al. Gut microbiota of adults with different metabolic phenotypes. Nutrition. 2021;90:111293.

39. Grahnemo L, Nethander M, Coward E, et al. Cross-sectional associations between the gut microbe Ruminococcus gnavus and features of the metabolic syndrome. The Lancet Diabetes & Endocrinology. 2022;10(7):481–483.

40. Wang SZ, Yu YJ, Adeli K. Role of gut microbiota in neuroendocrine regulation of carbohydrate and lipid metabolism via the microbiota-gut-brain-liver axis. Microorganisms. 2020;8(4):527.

41. Rios-Covian D, Salazar N, Gueimonde M, et al. Shaping the metabolism of intestinal Bacteroides population through diet to improve human health. Frontiers in microbiology. 2017;8:376.

42. Ussar S, Griffin NW, Bezy O, et al. Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome. Cell metabolism. 2015;22(3):516–530.

43. Larsen N., Vogensen FK, Van Den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PloS one. 2010;5(2):e9085.